Thomas Scientific, the nation's largest pure-play distributor of scientific products, has officially entered into a supplier partnership with Reditus Laboratories, LLC, d/b/a "GRD," a full-service pathology laboratory also specializing in PCR/molecular testing and anatomical/clinical pathology.
Reditus, which provides pathology and molecular services to healthcare facilities across Illinois, has also delivered more than 2,400,000 COVID-19 tests since April 2020. This significant uptick in the PCR testing portion of their business eventually prompted Reditus/GRD to develop real-time PCR assays and extraction kits made for RUO. These products are the primary initial focus of the distribution agreement with Thomas Scientific.
Reditus/GRD's Pathogen Extraction Reagents (RUO) provide a simple, reliable, and affordable alternative to other commercial reagents for nucleic acid extraction for downstream applications like PCR and NGS. The Reagents can be used with both manual and automated extraction methods, such as KingFisher FLEX systems. Reditus/GRD has also developed the FluV19 multiplex RT-PCR (RUO) assay capable of detecting SARS-CoV-2, Influenza A, and Influenza B. Additionally, detection of human RNase P is also included in the multiplex assay as an internal extraction control for sample matrixes containing human cells.
"Our intent, through partnership with Thomas Scientific, is to provide cost effective and reliable reagents for use in molecular biology," stated Dr. Joshua Geltz, Director of the Reditus Molecular Laboratory and Dr. Aaron Rossi, CEO in a joint statement. "Our strategy focuses on universal applications for molecular biology with fewer steps, greater reproducibility in recovery of extraction material, and increased confidence of quality results with real-time assays."
Founded in 1900, Thomas Scientific operated as a family-owned business for most of its history before being acquired by The Carlyle Group in 2017. This milestone provided the resources the company needed to make acquisitions of their own – thus expanding the strength of their distribution network and breadth of top-tier suppliers.
The combined impact of these growth initiatives has allowed Thomas to greatly enhance its life science capabilities, accentuated by a significant investment in their Molecular Diagnostics business unit this past January. The company is committed to serving every step of the molecular diagnostics workflow by providing the most innovative products available – like those offered by Reditus.
Reditus/GRD products provide Thomas Scientific with greater flexibility in the consultative workflow approach they take with customers. "The Reditus partnership greatly enhances the quality of custom solutions we can provide to clients," said Rebecca Nuss, Director of Life Sciences, Clinical, and Diagnostics for Thomas Scientific. "Their level of manufacturing innovation is a testament to the hands-on laboratory experience they have – and we're excited to see what's in store for the future of our relationship."
For more information to visit, http://www.thomassci.com
Reditus Laboratories, LLC is a full-service pathology laboratory located in Pekin, Illinois. We are committed to providing our clients with top-tier, accurate anatomical and clinical pathology services, as well as microbiology testing and PCR assays. Our leadership consists of medical professionals and physicians with many years of business and clinical experience who never forget what matters at the end of the day: service to the human being.